NEW YORK (GenomeWeb News) – Fluorotechnics today said that it is offering a one for five non-renouncable pro rata rights issue at A$.30 per share that it expects will bring in proceeds of A$1.8 million (US$1.6 million).

The Australian supplier of fluorescence and other protein detection technologies said that the shares are priced at a 14 percent discount to its closing price on the Australian Stock Exchange yesterday.

Fluorotechnics intends to use the proceeds for sales and marketing initiatives and as working capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.